Advanced search
Publication Cover
Biomarkers Volume 8, 2003 - Issue 1
Submit an article Journal homepage
239
Views
106
CrossRef citations to date
0
Altmetric
Research Article

Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity

Lucio G. Costa Department of Environmental Health, University of Washington, Seattle, Washington, USA
,
Rebecca J. Richter Department of Genome Sciences and Medicine, Division of Medical Genetics, University of Washington, Seattle, Washington, USA
,
Wan-Fen Li Department of Environmental Health, University of Washington, Seattle, Washington, USA
,
Toby Cole Department of Genome Sciences and Medicine, Division of Medical Genetics, University of Washington, Seattle, Washington, USA
,
Marina Guizzetti Department of Pharmacology and Physiology, University of Roma 'La Sapienza', Rome, Italy
&
Clement E. Furlong Department of Pharmacology and Physiology, University of Roma 'La Sapienza', Rome, Italy
Pages 1-12 | Published online: 29 Sep 2008

  • ABBOTT, C. A., MACKNESS, M. I., KUMAR, S., BOULTON, A. J. and DURRINGTON, P. N. 1995, Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arteriosclerosis, Thrombosis and Vascular Biology, 15, 1812-1818.
  • ADKINS, S., GAN, K.N., MODY, M. and LA DU, B. N. 1993, Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. American Journal of Human Genetics, 53, 598-608.
  • AKHMEDOVA, S., ANISIMOV, S., YAKIMOVSKY, A. and SCHWARTZ, E. 1999, Gln ? Arg 191 polymorphism of paraoxonase and Parkinson's disease. Human Heredity, 49, 178-180.
  • AKHMEDOVA, S. N., YAKIMOVSKY, A. K. and SCHWARTZ, E. I. 2001, Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. Journal of Neurological Sciences, 184, 179-182.
  • AUGUSTINSSON, K. B. and BARR, M. 1963, Age variation in plasma arylesterase activity in children. Clinica Chimica Acta, 8, 568-573.
  • BENKE, G. M. and MURPHY, S. D. 1975, The influence of age in the toxicity and metabolism of methylparathion and parathion in male and female rats. Toxicology and Applied Pharmacology, 31, 254-269.
  • BLATTER GARIAN, M. C., JAMES, R. W., DUSSIOX, P., BLANCHE, M., PASSA, P., FROGUEL, P. and RUIZ, J. 1997, Paraoxonase polymorphism Met-Leu 54 associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. Journal of Clinical Investigation, 99, 62-66.
  • BREALEY, C. B., WALKER, C. H. and BALDWIN, B. C. 1980, A-esterase activities in relation to the differential toxicity of pirimiphos-methl to birds and mammals. Pesticide Science, 11, 546-554.
  • BROPHY, V. M., HASTINGS, M. D., CLENDENNING, J. B., RICHTER, R. J., JARVIK, G. P. and FURLONG, C. E. 2001a, Polymorphisms in the human paraxonase (PON1) promoter. Pharmacogenetics, 11, 77-84.
  • BROPHY, V. H., JAMPSA, R. L., CLENDENNING, J. B., MCKINSTRY, L. A. and FURLONG, C. E. 2001b, Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. American Journal of Human Genetics, 68, 1428-1436.
  • BROPHY, V. H., JARVIK, G. P. and FURLONG, C. E. 2002, PON1 polymorphisms. In Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects, edited by L. G. Costa and C. E. Furlong (Norwell, Massachusetts: Kluwer Academic Publishers), in press.
  • CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY. 1998, Report for the Application and Ambient Air Monitoring of Chlorphyrifos (and the Oxon Analogue) in Tulare County During Spring/Summer 1996. Projects No. C96-040 and C96-041, p. 28.
  • COSTA, L. G. 1997, Basic toxicology of pesticides. Occupational Medicine, 12, 251-268.
  • COSTA, L. G. 2000, The emerging field of ecogenetics. Neurotoxicology, 21, 85-89.
  • COSTA, L. G. 2001, Pesticide exposure: differential risk for neurotoxic outcomes due to enzyme polymorphisms. Clinics in Occupational and Envionmental Medicine, 1, 511-523.
  • COSTA, L. G. 2001, Pesticide exposure: differential risk for neurotoxic outcomes due to enzyme polymorphisms. Clinics in Occupational and Environmental Medicine, 1, 511-523.
  • COSTA, L. G., RICHTER, R. J., MURPHY, S. D., OMENN, G. S., MOTULSKY, A. G. and FURLONG, C. E. 1987, Species differences in serum paraoxonase correlate with sensitivity to paraoxon toxicity. In Toxicology of Pesticides: Experimental, Clinical and Regulatory Perspectives, edited by L. G. Costa, C. L. Galli and S. D. Murphy (Heildelberg: Springer-Verlag), pp. 262-266.
  • COSTA, L. G., MCDONALD, B. E., MURPHY, S. D., RICHTER, R. J., MOTULSKY, A. G. and FURLONG, C. E. 1990, Serum paraoxonase and its influence on paraoxon and chlorphyrifos oxon toxiciy in rats. Toxicology and Applied Pharmacology, 103, 66-76.
  • COWAN, J., SINTON, C. M., VARLEY, A. W., WIANS, F. H., HALEY, R. W. and MUNFORD, R. S. 2001, Gene therapy to prevent organophosphate intoxication. Toxicology and Applied Pharmacology, 173, 1-6.
  • DAM, K., SEIDLER, F. J. and SLOTKIN, T. A. 2000, Chlorpyrifos exposure during a critical neonatal period elicits gender-selective deficits in the development of coordination skills and locomotor activity. Developmental Brain Research, 121, 179-187.
  • DAVIES, H. G., RICHTER, R. J., KEIFER, M., BROOMFIELD, C. A., SOWALLA, J. and FURLONG, C. E. 1996, The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genetics, 14, 334-336.
  • DRAGANOV, D. L., STETSON, P. L., WATSON, C. E., BILLECKE, S. S. and LA DU, B. N. 2000, Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein associated lactonase and protects low density lipoprotein against oxidation. Journal of Biological Chemistry, 275, 33435-33442.
  • DURRINGTON, P. N., MACKNESS, B. and MACKNESS, M. J. 2001, Paraoxonase and atherosclerosis. Arteriosclerosis. Thrombosis and Vascular Biology, 21, 473-480.
  • EATON, D. L., FARIN, F., OMIECINSKI, C. J. and OMENN, G. S. 1988, Genetic susceptibility. In Environmental and Occupational Medicine, edited by W. N. Rom (Philadelphia: Lippincott-Raven), pp. 209-221.
  • ECKERSON, H. W., WHITE, C. M. and LA DU, B. N. 1983, The human serum paraoxonase/arylesterase polymorphism. American Journal of Human Genetics, 35, 1126-1138.
  • ESKENAZI, B., BRADNAM, A. and CASTORINA, R. 1999, Exposure of children to organophosphate pesticides and their potential adverse health effects. Environmental Health Perspectives, 107, Supplement 3, 409-419.
  • FAHN, S. and COHEN, G. 1992, The oxidant stres hypothesis in Parkinson's disease: evidence supporting it. Annals of Neurology, 32, 504-812.
  • FERRÈ, N., CAMPS, J., CABRE, M., PAUL, A. and JOVEN, J. 2001, Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism, 50, 997-1000.
  • FURLONG, C.E., RICHTER, R. J., CHAPLINE, C. and CRABB, J. W. 1991, Purification of rabbit and human serum paraoxonase. Biochemistry, 30, 10133-10140.
  • GAN, K.N., SMOLEN, A., ECKERSON, H.W. and LA DU, B.N. 1991, Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metabolism and Disposition, 19, 100-106.
  • GELDMACHER-VON MALLICKRODT, M. and DIEPGEN, T. L. 1988, The human serum paraoxonase polymorphism and specificity. Toxicology and Environmental Chemistry, 18, 79-196.
  • HASSETT, C. RICHTER, R. J., HUMBERT, R., CHAPLINE, C., CRABB, J. W., OMIECINSKI, C. J. and FURLONG, C. E. 1991, Characterization of DNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry, 30, 10141-10149.
  • HUMBERT, R., ADLER, D. A., DISTECHE, C. M., HASSETT, C., OMIECINSKI, C. J. and FURLONG, C. E. 1993, The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics, 3, 73-76.
  • IKEDA, T., OBAYASHI, H., HASEGAWA, G., NAKAMURA, N., YOSHIKAWA, T., IMAMURA, Y., KOIZUMI, K. and KINOSHITA, S. 2001, Paraoxonase gene polymorphisms and plasma oxidized low-density lipoprotein level as possible risk factors for exudative age-related macular degeneration. American Journal of Ophthalmology, 132, 191-195.
  • INOUE, M., SUEHIRO, T., NAKAMURA, T., IKEDA, Y., KUMON,Y. and HASHIMOTO, L. 2000, Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism, 49, 1400-1405.
  • JARVIK, G. P., ROZEK, L. S., BROPHY, V. H., HATSUKAMI, T. S., RICHTER, R. J., SCHELLENBERG, G. D. and FURLONG, C. E. 2000, Paraoxonase (PON1) phenotype is a better predictor of vascular disease than in PON1192 or PON155 genotype. Arterosclerosis, Thrombosis and Vascular Biology, 20, 2441-2447.
  • KONDO, I. and YAMAMOTO, M. 1998, Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Research, 806, 271-273.
  • LEVIEV, I. and JAMES, R. W. 2000, Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arteriosclerosis, Thrombosis and Vascular Biology, 20, 516-521.
  • LEVIEV, I., KALIX, B., BRULHART MEYNET, M. C. and JAMES, R.W. 2001a, The paraoxonase PON1 promoter polymorphism C(-107)T is associated with increased serum glucose concentrations in non-diabetic patients. Diabetologia, 44, 1177-1183.
  • LEVIEV, I., RIGHETTI, A. and JAMES, R. W. 2001b, Paraoxonase promoter polymorphism T(--107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. Journal of Molecular Medicine, 79, 457-463.
  • LI, W. F., COSTA, L. G. and FURLONG, C. E. 1993, Serum paraoxonase status: a major factor in determining resistance to organophosphates. Journal of Toxicology and Environmental Health, 40, 337-346.
  • LI, W. F., FURLONG, C. E. and COSTA, L. G. 1995, Paraoxonase protects against chloropyrifos toxicity in mice. Toxicology Letters, 76, 219-226.
  • LI, W. F., MATHEWS, C., DISTECHE, C. M., COSTA, L. G. and FURLONG, C. E. 1997, Paraoxonase (PON1) gene in mice: sequencing, chromosomal localization and developmental expression. Pharmacogenetics, 7, 137-144.
  • LI, W. F., COSTA, L. G., RICHTER, R. J., HAGEN, T., SHIH, D. M., TWARD, A., LUSIS, A. J. and FURLONG, C. E. 2000, Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphates. Pharmacogenetics, 10, 1-13.
  • LOTTI, M. 2000, Organophosphorus compounds. In Experimental and Clincal Neurotoxicology, edited by P. S.Spencer, M. Schaumburg and A. C. Ludolph (Oxford: Oxford University Press), pp. 898-925.
  • MACKNESS, M. I., ARROL, S., ABBOTT, C. A. and DURRINGTON, P. N. 1993, Protection of low-density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis, 104, 129-135.
  • MACKNESS, B., DAVIES, G. K., TURKIE, W., LEE, E., ROBERTS, D. H., MILL, E., ROBERTS, C., DURRINGTON, P. N. and MACKNESS, M. I. 2001, Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype? Arteriosclerosis, Thrombosis and Vascular Biology, 21, 1461-1467.
  • MACKNESS, B., MACKNESS, M. I., ARROL, S., TURKIE, W., JULIER, K., ABUASHA, B., MILLER, J. E., BOULTON, A. J. and DURRINGTON, P. N. 1998a, Serum paraoxonase (PON1) 55 and 192 polymorphisms and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis, 139, 341-349.
  • MACKNESS, B., MACKNESS, M. I., ARROL, T., TURKIE, W. and DURRINGTON, P. N. 1998b, Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letters, 423, 57-60.
  • MAIN, A. R. 1956, The role of a A-esterase in the acute toxicity of paraoxon, TEPP and parathion. Canadian Journal of Biochemistry and Physiology, 34, 197-216.
  • MOCHIZUKI, H., SCHERER, S. W., XI, T., NICKLE, D. C., MAYER, M., HUIZENGA, J. J., TSUI, L. C. and PROCHAZKA, M. 1998, Human PON2 gene at 7q21.3: cloning, multiple RNA forms, and missense polymorphisms in the coding sequence. Gene, 213, 149-157.
  • MORETTO, A., CAPODICASA, E., PERAICA, M. and LOTTI, M. 1991, Age sensitivity to organophosphate-induced delayed polyneuropathy. Biochemical and toxicological studies in developing chicks. Biochemical Pharmacology, 10, 1497-1504.
  • MORTENSEN, S. R., CHANDA, S. M., HOOPER, M. J. and PADILLA, S. 1996, Maturational difference in chlorphyrifos-oxonase activity may contribute to age-related sensitivity to chlorpyrifos. Journal of Biochemical Toxicology, 11, 279-287.
  • MUELLER, R. F., HORNUNG, S., FURLONG, C., ANDERSON, J., GIBLETT, E. R. and MOTULSKY, A. G. 1983, Plasma paroxonase polymorphism: a new enzyme assay, population, family, biochemical and linkage studies. American Journal of Human Genetics, 35, 393-408.
  • NG, C. J., WADLEIGH, D. J., GANGOPADHYAY, A., HAMA, S., GRIJALVA, V. R., NAVAB, M., FOGELMAN, A. M. and REDDY, S. T. 2001, Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. Journal of Biological Chemistry, 246, 44444-44449.
  • OHBU, S., YAMASHINA, A., TAKASU, N., YAMAGUCHI, T.,MURAI, T., KAKANO, K., MATSUI, Y., MIKAMI, R., SAKURAI, K. and HINOHARA, S. 1997, Sarin poisoning on Tokyo subway. South Medical Journal, 90, 587-593.
  • PADILLA, S., BUZZARD, J. and MOSER, V. V. 2000, Comparison of the role of esterases in the differential age-related sensitivity to chlorpyrifos and metamidophos. Neurotoxicology, 21, 49-56.
  • POND, A. L., CHAMBERS, H. W. and CHAMBERS, J. E. 1995, Organophosphate detoxication potential of various rat tissues via A-esterases and alieterase activities. Toxicology Letters, 78, 245-252.
  • POPE, C. N. and LIU, J. 1997, Age-related difference in sensitivity to organophosphorus pesticides. Environmental Toxicology and Pharmacology, 4, 309-314.
  • PRIMO-PARMO, S. L., SORENSON, R. E., TEIBER, J. and LA DU, B. N. 1996, The human serum paraoxonase/arylesterase gene (PON1) is a member of a multigene family. Genomics, 33, 498-509.
  • PRIYADARSHI, A., KHUDER, S. A., SCHAUB, E. A. and PRIYADARSHI, S. S. 2001, Environmental risk factors and Parkinson's disease: a metaanalysis. Environmental Research Section A, 86, 122-127.
  • RICHTER, R. J. and FURLONG, C. E. 1999, Determination of paraoxonase (PON1) status require more than genotyping. Pharmacogenetics, 9, 745-753.
  • SHEETS, L. P. 2000, A consideration of age-dependent differences in susceptibility to organophosphorus and pyrethroid insecticides. Neurotoxicology, 21, 57-64.
  • SHIH, D. M., GU, L., XIA, Y. R., NAVAB, M., LI, W. F., HAMA, S., CASTELLANI, L. W., FURLONG, C. E., COSTA, L. G., FOGELMAN, A. M. and LUSIS, A. J. 1998, Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and artherosclerosis. Nature, 394, 284-298.
  • SHIH, D. M., REDDY, S. and LUSIS, A. J. 2002, CHD and atherosclerosis: human epidemiological studies and transgenic animal models. In Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects, edited by L. G. Costa and C. E. Furlong (Norwell, Massachusetts: Kluwer Academic Publishers), in press.
  • SUEHIRO, T., NAKAMURA, T., INOUE, M., SHINOKI, T., IKEDA, Y., KUMON, Y., SHINDO, M., TANAKA, H. and HASHIMOTO, K. 2000, A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis, 150, 295-298.
  • WANG, J. and LIU, Z. 2000, No association between paraoxonase (PON1) gene polymorphisms and susceptibility to Parkinson's disease in a Chinese population. Movement Disorders, 15, 1265-1267.
  • WATSON, A. D., BERLINER, J. A., HAMA, S. Y., LA DU, B. N., FAULL, K. F., FOGELMAN, A. M. and NAVAB, M. 1995, Protective effect of high density lipoprotein-associated paraoxonase: inhibition of the biological activity of minimally oxidized low-density lipoproteins. Journal of Clinical Investigation, 96, 2882-2891.
  • WHO. 1990, Public Health Impact of Pesticides Used in Agriculture (Geneva: World Health Organization).
  • YUKNAVAGE, K. L., FENSKE, R. A., KALMAN, D. A., KEIFER, M. C. and FURLONG, C. E. 1997, Simulated dermal contamination with capillary samples and field cholinesterase biomonitoring. Journal of Toxicology and Environmental Health, 51, 35-45.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.